NeuroVive Pharmaceutical AB (publ) board of directors announced that it has selected Erik Kinnman as NeuroVive's Chief Executive Officer. Erik Kinnman will assume the new role on the 14 March 2016, leaving Chief Medical Officer and Chief Operating Officer roles within his own consultancy business. Erik Kinnman succeeds interim CEO Jan Nilsson, who will resume his position as Chief Operating Officer for NeuroVive.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2205 SEK | +1.38% |
|
+16.17% | -10.18% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.18% | 27.64M | |
+20.01% | 126B | |
+24.33% | 118B | |
+25.09% | 27.87B | |
-17.38% | 20.95B | |
-14.87% | 16.92B | |
-14.18% | 16.18B | |
+10.75% | 14.84B | |
-47.10% | 14.79B | |
+54.43% | 14.08B |
- Stock Market
- Equities
- ABLI Stock
- News Abliva AB
- NeuroVive Pharmaceutical AB Announces Executive Changes